Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a...

  • Main
  • 2020 / 4
  • Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a...
Clinical Lymphoma Myeloma and Leukemia 2020 / 4

Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation

Hua, Jingsheng, Zhang, Jian, Wu, Xiaoxia, Zhou, Lili, Bao, Xiebing, Han, Yue, Miao, Miao, Li, Caixia, Fu, Zhengzheng, Wu, Depei, Qian, Weiqing, Qiu, Huiying
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
Clinical Lymphoma Myeloma and Leukemia
DOI:
10.1016/j.clml.2020.04.007
Date:
April, 2020
File:
PDF, 344 KB
2020
Conversion to is in progress
Conversion to is failed